PMN Stock Analysis: Buy, Sell, or Hold?
PMN - ProMIS Neurosciences Inc. Common Shares (ON)
$9.40
0.02 (0.21%)
▲
5d:
-16.59%
30d:
-32.74%
90d:
-31.44%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When PMN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PMN is down 16.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PMN is down 16.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: PMN is currently trading at $9.40, which is considered oversold relative to its 30-day fair value range of $11.27 to $14.09.
Technical Outlook: Technically, PMN is in a uptrend. The price is currently testing key support at $9.16. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $42.61 (+353.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PMN is in a uptrend. The price is currently testing key support at $9.16. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $42.61 (+353.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$11.27 -
$14.09
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (43/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 353.3% below Wall St target ($42.61)
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$11.27 -
$14.09
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$9.16
Resistance Level
$14.22
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.68
Wall Street Target
$42.61
(+353.3%)
Share & Embed Analysis
Last updated: October 04, 2026 11:47 AM ET
Data refreshes hourly during market hours. Next update: 12:47 PM
Data refreshes hourly during market hours. Next update: 12:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PMN showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Patrick D Kirwin
BUY
4000 shares
2026-04-22
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
23 analysts |
$257 | 53 HOLD |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 73 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$74 | 60 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
20 analysts |
$95 | 57 HOLD |
|
SNDX
Syndax Pharmaceuticals I… |
STRONG BUY
12 analysts |
$38 | 70 BUY |
